Impact of preload changes on positive and negative left ventricular dP/dt and systolic time intervals: preload changes on left ventricular function

Jamshidi, Peiman; Kobza, Richard; Toggweiler, Stefan; Arand, Patti; Züber, Michel; Erné, Paul

doi:10.1016/s0019-4832(12)60095-9

Cited by 7 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acoustic cardiography was chosen since it is simple and more reproducible than echocardiography in the context of pacing therapy optimization . The principal parameter for the optimization was the electromechanical activation time (EMAT) which correlates well with LV function . Time between the RV/LV and PIDS pacing pulse was adjusted from −40 to +40 ms in steps of 10 ms and was considered optimized if EMAT was minimized.…”

Section: Methodsmentioning

confidence: 99%

Improvement of cardiac function with device‐based diaphragmatic stimulation in chronic heart failure patients: the randomized, open‐label, crossover Epiphrenic II Pilot Trial

Beeler

Schoenenberger

Bauer³

et al. 2013

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

AimsDevice-based pacing-induced diaphragmatic stimulation (PIDS) may have therapeutic potential for chronic heart failure (HF) patients. We studied the effects of PIDS on cardiac function and functional outcomes. Methods and resultsIn 24 chronic HF patients with CRT, an additional electrode was attached to the left diaphragm. Randomized into two groups, patients received the following PIDS modes for 3 weeks in a different sequence: (i) PIDS off (control group); (ii) PIDS 0 ms mode (PIDS simultaneously with ventricular CRT pulse); or (iii) PIDS optimized mode (PIDS with optimized delay to ventricular CRT pulse). For PIDS optimization, acoustic cardiography was used. Effects of each PIDS mode on dyspnoea, power during exercise testing, and LVEF were assessed. Dyspnoea improved with the PIDS 0 ms mode (P = 0.057) and the PIDS optimized mode (P = 0.034) as compared with the control group. Maximal power increased from median 100.5 W in the control group to 104.0 W in the PIDS 0 ms mode (P = 0.092) and 109.5 W in the PIDS optimized mode (P = 0.022). Median LVEF was 33.5% in the control group, 33.0% in the PIDS 0 ms mode, and 37.0% in the PIDS optimized mode (P = 0.763 and P = 0.009 as compared with the control group, respectively).

show abstract

Section: Methodsmentioning

confidence: 99%

Improvement of cardiac function with device‐based diaphragmatic stimulation in chronic heart failure patients: the randomized, open‐label, crossover Epiphrenic II Pilot Trial

Beeler

Schoenenberger

Bauer³

et al. 2013

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since heart rate and myocardial contractility (dP/dtmax) was held constant, the increase in coronary blood flow was due to an augmentation in stroke volume and expansion of the coronary arteries. After myocardial, cardiac preload, and afterload gradually increased eventually leading to more debilitating heart function [ 43 , 44 ]. LVEDP and CVR were used as indicators of cardiac preload and afterload [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

Protective effect of Suxiao jiuxin pill, a traditional Chinese medicine, against acute myocardial ischemia in dogs

Zhang

Zhuang

et al. 2015

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to investigate the effect of Suxiao Jiuxin Pill (SX), a traditional Chinese medicine, on acute myocardial ischemia induced by coronary occlusion in anesthetized dogs.MethodsAcute myocardial ischemia model was established by ligating the left anterior descending artery to reduce flow by 90 %. Adult mongrel dogs were randomly divided into six groups: model, SX high dose, SX middle dose, SX low dose, Isosorbide dinitrate (ISD) and Sham groups. Adult mongrel dogs were anesthetized and instrumented for measurements of heart rate (HR), mean arterial pressure (MAP), left ventricular systolic pressure (LVSP), left ventricular dP/dt, coronary blood flow (CBF), myocardial blood flow (MBF), coronary vascular resistance (CVR), and epicardial electrocardiogram (EECG). After administration with SX, changes in hemodynamics were recorded. Serum enzymes and blood gas analysis were also detected.ResultsSX has a dose-dependent effect on the reduction of infarct size. Besides, SX exerted a notable inhibition on the elevation of serum creatine kinase MB (CK-MB), lactate dehydrogenase (LDH), malondialdehyde (MDA), and elevation in the superoxide dismutase (SOD) activity. SX also showed a capacity to recover myocardial function by significantly reducing MAP, CVR, LVSP, left ventricular systolic pressure (LVEDP), systolic blood pressure (SBP), diastolic blood pressure (SDP), and increasing CBF and myocardial blood flow (MBF). In addition, SX high dose group markedly reduced total mV of ST segment elevation (Σ-ST), total number of sites with this degree of ST segment elevation (N-ST) and oxygen extraction ratio (O2 Extr).ConclusionSX can improve hemodynamic and myocardial oxygen metabolism, reduce the degree and scope of myocardial ischemia, and hence exert notable anti-anginal ischaemic effect.

show abstract

“…It measures the amount of time that the left ventricle requires to generate sufficient force to close the mitral valve . It has been shown that EMAT and %EMAT are closely related to left ventricular contractility . Reduced left ventricular contractility is present in patients with heart failure, and may precede the development of reduced ejection fraction .…”

Section: Discussionmentioning

confidence: 99%

The Clinical Value of Echocardiography and Acoustic Cardiography to Monitor Patients Undergoing Anthracycline Chemotherapy

Toggweiler

Odermatt

Brauchlin

et al. 2012

Clinical Cardiology

Self Cite

View full text Add to dashboard Cite

Background: Investigate the usefulness of echocardiography and acoustic cardiography to monitor patients exposed to anthracycline chemotherapy. Hypothesis: Serial echocardiographies to monitor systolic function may not be neccessary in all patients undergoing anthracycline chemotherapy. Methods: In a prospective study, consecutive patients undergoing anthracycline-containing chemotherapy were evaluated with echocardiography and acoustic cardiography at baseline, after completion of chemotherapy, and after a median follow-up of 3.8 years. Systolic dysfunction was defined as a left ventricular ejection fraction ≤50%. Results: A total of 187 patients (83% female) with a mean age of 55 ± 14 years underwent chemotherapy for breast cancer (73%), malignant lymphoma (23%), and sarcoma (4%). None of the patients had systolic dysfunction at baseline. Patients were treated with doxorubicin 276 ± 74 mg/m 2 or epirubicin 317 ± 55 mg/m 2 .After chemotherapy, 170 (91%) had normal systolic function, 8 (4%) developed systolic dysfunction, and 9 (5%) had died. Of those 8 patients with systolic dysfunction, 4 (50%) improved to normal systolic function, 1 (13%) remained unchanged, and 3 (37%) died. Patients with normal systolic function after chemotherapy had a mortality rate of 3.5%, and 1.8% developed late systolic dysfunction. Acoustic cardiography-derived percent electromechanical activation time >12.4% had a sensitivity of 88% and a specificity of 84% to identify patients with systolic dysfunction (area under the receiver operating characteristic curve 0.87). Conclusions:Patients with systolic dysfunction early after anthracycline treatment had worse outcome. Acoustic cardiography was able to identify these patients with a high sensitivity and specificity. Based on the findings of this study, we propose a simple algorithm to monitor patients undergoing anthracycline-containing chemotherapy.

show abstract

Impact of preload changes on positive and negative left ventricular dP/dt and systolic time intervals: preload changes on left ventricular function

Cited by 7 publications

References 19 publications

Improvement of cardiac function with device‐based diaphragmatic stimulation in chronic heart failure patients: the randomized, open‐label, crossover Epiphrenic II Pilot Trial

Improvement of cardiac function with device‐based diaphragmatic stimulation in chronic heart failure patients: the randomized, open‐label, crossover Epiphrenic II Pilot Trial

Protective effect of Suxiao jiuxin pill, a traditional Chinese medicine, against acute myocardial ischemia in dogs

The Clinical Value of Echocardiography and Acoustic Cardiography to Monitor Patients Undergoing Anthracycline Chemotherapy

Contact Info

Product

Resources

About